Details of Disease

General Information of Disease (ID: DIS8KLVM)

Disease Name	Acute graft versus host disease
Synonyms	acute GVHD; fulminant graft versus host disease; GVHD, acute; acute graft vs. host disease; graft versus host disease, acute
Disease Class	4B24: Graft-versus-host disease
Definition	A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.
Disease Hierarchy	DIS0QADF: Graft-versus-host disease DISBV50J: Acute disease DIS8KLVM: Acute graft versus host disease
ICD Code	ICD-11 ICD-11: 4B24.0 ICD-10 ICD-10: T86.0 ICD-9 ICD-9: 279.51 Expand ICD-11 '4B24.0 Expand ICD-10 'T86.0 Expand ICD-9 279.51
Disease Identifiers	MONDO ID MONDO_0020546 UMLS CUI C0856825 MedGen ID 208987 Orphanet ID 99920 SNOMED CT ID 402355000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Pentostatin	DM0HXDS	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RG6287	DMNGIX3	Phase 1	Fusion protein	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 30 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CCR7	TT2GIDQ	Limited	Biomarker	[3]
PECAM1	TT4EZB2	Limited	Biomarker	[4]
ITGB7	TTLT9XQ	moderate	Biomarker	[5]
MASP2	TTR01E9	moderate	Genetic Variation	[6]
PTAFR	TTQL5VC	moderate	Biomarker	[7]
QPCT	TTJ7YTV	moderate	Genetic Variation	[8]
AREG	TT76B3W	Strong	Altered Expression	[9]
BPI	TTXCSDR	Strong	Genetic Variation	[10]
C3AR1	TTI6B3F	Strong	Biomarker	[11]
CD28	TTQ13FT	Strong	Biomarker	[12]
CD52	TTQT5S9	Strong	Biomarker	[13]
CD83	TTT9MRQ	Strong	Biomarker	[14]
DAAM2	TTN0Z6H	Strong	Genetic Variation	[15]
FBXO3	TTUX14L	Strong	Genetic Variation	[16]
FST	TTDNM9W	Strong	Genetic Variation	[17]
IL10RB	TTJTRMK	Strong	Genetic Variation	[18]
IL18RAP	TTZUJVE	Strong	Altered Expression	[19]
IL23R	TT6H4QR	Strong	Genetic Variation	[10]
IL7R	TTAWI51	Strong	Genetic Variation	[20]
IL9	TT0JTFD	Strong	Biomarker	[21]
IMPDH1	TT3GRLK	Strong	Genetic Variation	[22]
ITGA2	TTSJ542	Strong	Biomarker	[23]
KIR2DS2	TTV3CFI	Strong	Genetic Variation	[24]
MADCAM1	TTBD6I7	Strong	Genetic Variation	[25]
OAT	TTTSCQ2	Strong	Biomarker	[26]
S1PR1	TT9JZCK	Strong	Posttranslational Modification	[27]
SCT	TTOBVIN	Strong	Genetic Variation	[28]
SELL	TT2IYXF	Strong	Biomarker	[29]
TIGIT	TTWNL74	Strong	Altered Expression	[30]
IL22	TTLDX4N	Definitive	Biomarker	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 30 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A37	DTLBGTZ	Strong	Biomarker	[32]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
NDUFS3	DE741FI	Limited	Genetic Variation	[33]
NDUFS7	DEIW03B	Strong	Genetic Variation	[34]
------------------------------------------------------------------------------------

This Disease Is Related to 34 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
METTL8	OT7E09Y4	Limited	Biomarker	[35]
SERPINF2	OTZGAF8B	Limited	Biomarker	[36]
TIPRL	OTS2FZ8O	Limited	Biomarker	[35]
DOCK11	OTFSTN6A	moderate	Genetic Variation	[37]
GLCCI1	OTU0R1CU	moderate	Genetic Variation	[38]
KRT15	OTS6WLF7	moderate	Altered Expression	[39]
P2RX2	OT0LF34A	moderate	Altered Expression	[40]
SUFU	OT0IRYG1	moderate	Genetic Variation	[41]
TLR10	OTQ1KVJO	moderate	Genetic Variation	[42]
ARHGAP45	OTL86FEQ	Strong	Biomarker	[43]
CLEC7A	OTRTBH27	Strong	Genetic Variation	[44]
DEFA5	OT95CBQ9	Strong	Genetic Variation	[45]
DHX15	OT4F98TK	Strong	Biomarker	[46]
FANCB	OTMZTXB5	Strong	Biomarker	[47]
HCST	OTILCB4K	Strong	Genetic Variation	[48]
HLA-DPA1	OT7OG7Y2	Strong	Biomarker	[49]
HLA-DRB3	OT5PM9N7	Strong	Biomarker	[50]
HLA-E	OTX1CTFB	Strong	Genetic Variation	[51]
HSPA1L	OTC2V1K6	Strong	Altered Expression	[52]
IL17RC	OTEFOBSS	Strong	Biomarker	[53]
IL27RA	OTSQBAKI	Strong	Altered Expression	[54]
ITFG1	OTX0PCR3	Strong	Biomarker	[55]
KIR2DS4	OT00N6UJ	Strong	Biomarker	[56]
KIR3DS1	OTJWIO4T	Strong	Biomarker	[57]
MICA	OTPEIEAR	Strong	Biomarker	[58]
NLGN4Y	OT7E1S57	Strong	Biomarker	[59]
NRM	OTK7F9XZ	Strong	Biomarker	[60]
PSG1	OT1U4ZZW	Strong	Biomarker	[61]
PUM3	OTN1IPNS	Strong	Biomarker	[62]
TAPBP	OTL81AVZ	Strong	Biomarker	[63]
TBCE	OTGBSTKS	Strong	Genetic Variation	[64]
TNFAIP8	OT1G9297	Strong	Biomarker	[65]
TNMD	OTHLVA9G	Strong	Biomarker	[48]
PI3	OT47MTC3	Definitive	Biomarker	[66]
------------------------------------------------------------------------------------


⏷ Show the Full List of 34 DOT(s)

References

1	Pentostatin FDA Label
2	Clinical pipeline report, company report or official report of Roche
3	R707, a fully human antibody directed against CC-chemokine receptor 7, attenuates xenogeneic acute graft-versus-host disease.Am J Transplant. 2019 Jul;19(7):1941-1954. doi: 10.1111/ajt.15298. Epub 2019 Mar 13.
4	Pre-transplantation thymic function is associated with the risk of acute graft versus host disease and cytomegalovirus viremia after allogeneic hematopoietic stem cell transplantation.Hematology. 2018 Jan;23(1):30-37. doi: 10.1080/10245332.2017.1327504. Epub 2017 May 22.
5	Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-7 during Acute Graft-versus-Host Disease of the Liver.Biol Blood Marrow Transplant. 2015 Dec;21(12):2069-2078. doi: 10.1016/j.bbmt.2015.08.038. Epub 2015 Sep 5.
6	Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation.Exp Hematol. 2006 Oct;34(10):1435-41. doi: 10.1016/j.exphem.2006.06.005.
7	Platelet-activating factor receptor plays a role in the pathogenesis of graft-versus-host disease by regulating leukocyte recruitment, tissue injury, and lethality.J Leukoc Biol. 2012 Apr;91(4):629-39. doi: 10.1189/jlb.1111561. Epub 2012 Feb 1.
8	RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation.Acta Haematol. 2013;129(3):137-45. doi: 10.1159/000343273. Epub 2012 Nov 30.
9	Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid.Mod Pathol. 2019 Apr;32(4):560-567. doi: 10.1038/s41379-018-0170-z. Epub 2018 Nov 13.
10	Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.Biol Blood Marrow Transplant. 2010 Dec;16(12):1718-27. doi: 10.1016/j.bbmt.2010.06.001. Epub 2010 Jun 9.
11	Antigen-presenting cell-derived complement modulates graft-versus-host disease.J Clin Invest. 2012 Jun;122(6):2234-8. doi: 10.1172/JCI61019. Epub 2012 May 15.
12	During acute graft versus host disease CD28 deletion in donor CD8(+) , but not CD4(+) , Tcells maintain antileukemia responses in mice.Eur J Immunol. 2018 Dec;48(12):2055-2067. doi: 10.1002/eji.201847669. Epub 2018 Nov 14.
13	A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease.Haematologica. 2012 Oct;97(10):1532-8. doi: 10.3324/haematol.2011.059980. Epub 2012 Apr 4.
14	CD83 Antibody Inhibits Human B Cell Responses to Antigen as well as Dendritic Cell-Mediated CD4 T Cell Responses.J Immunol. 2018 May 15;200(10):3383-3396. doi: 10.4049/jimmunol.1700064. Epub 2018 Apr 11.
15	DAAM2 polymorphism is closely related to the clinical outcomes of allogeneic hematopoietic stem cell transplantation.Ann Hematol. 2012 Apr;91(4):571-6. doi: 10.1007/s00277-011-1325-x. Epub 2011 Sep 10.
16	Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study.Bone Marrow Transplant. 2019 Jun;54(6):894-902. doi: 10.1038/s41409-018-0356-5. Epub 2018 Oct 19.
17	Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2020 Mar;26(3):606-611. doi: 10.1016/j.bbmt.2019.11.006. Epub 2019 Nov 10.
18	IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation.Transplantation. 2009 Mar 15;87(5):704-10. doi: 10.1097/TP.0b013e318195c474.
19	Increased expression of interleukin-18 receptor on T lymphocytes in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation.J Interferon Cytokine Res. 2002 Jul;22(7):751-4. doi: 10.1089/107999002320271332.
20	Donor Genotype in the Interleukin-7 Receptor -Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.Front Immunol. 2018 Feb 2;9:109. doi: 10.3389/fimmu.2018.00109. eCollection 2018.
21	Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation.Am J Transl Res. 2017 Aug 15;9(8):3623-3632. eCollection 2017.
22	Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2012 Feb;18(2):273-9. doi: 10.1016/j.bbmt.2011.06.014. Epub 2011 Jul 13.
23	Impact of disparity of minor histocompatibility antigens HA-1, CD31, and CD49b in hematopoietic stem cell transplantation of patients with chronic myeloid leukemia with sibling and unrelated donors.Transplantation. 2004 Apr 15;77(7):1103-6. doi: 10.1097/01.tp.0000120175.25116.cb.
24	KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA matched, hematopoietic stem cell transplantation.Bone Marrow Transplant. 2009 Jul;44(2):97-103. doi: 10.1038/bmt.2008.432. Epub 2009 Jan 26.
25	Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation.Hum Immunol. 2009 Jun;70(6):457-60. doi: 10.1016/j.humimm.2009.03.008. Epub 2009 Mar 12.
26	Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?.Biol Blood Marrow Transplant. 2004 Feb;10(2):128-34. doi: 10.1016/j.bbmt.2003.10.001.
27	Obese donor mice splenocytes aggravated the pathogenesis of acute graft-versus-host disease via regulating differentiation of Tregs and CD4(+) T cell induced-type I inflammation.Oncotarget. 2017 Aug 24;8(43):74880-74896. doi: 10.18632/oncotarget.20425. eCollection 2017 Sep 26.
28	Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.Ann Hematol. 2019 May;98(5):1267-1277. doi: 10.1007/s00277-019-03636-8. Epub 2019 Feb 12.
29	Expression of CD62L on donor CD4(+) T cells in allografts: correlation with graft-versus-host disease after unmanipulated allogeneic blood and marrow transplantation.J Clin Immunol. 2009 Sep;29(5):696-704. doi: 10.1007/s10875-009-9293-9. Epub 2009 May 22.
30	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.Biol Blood Marrow Transplant. 2019 May;25(5):861-867. doi: 10.1016/j.bbmt.2019.01.013. Epub 2019 Jan 11.
31	Regeneration After Radiation- and Immune-Mediated Tissue Injury Is Not Enhanced by Type III Interferon Signaling.Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):970-976. doi: 10.1016/j.ijrobp.2018.11.038. Epub 2018 Nov 29.
32	A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2020 May;26(5):835-844. doi: 10.1016/j.bbmt.2019.08.029. Epub 2019 Sep 7.
33	Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.Cancer Cell Int. 2018 Apr 23;18:62. doi: 10.1186/s12935-018-0553-8. eCollection 2018.
34	Transplant results in adults with Fanconi anaemia.Br J Haematol. 2018 Jan;180(1):100-109. doi: 10.1111/bjh.15006. Epub 2017 Nov 2.
35	TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model.Nat Biotechnol. 2003 Mar;21(3):302-7. doi: 10.1038/nbt797. Epub 2003 Feb 24.
36	A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD.Blood Adv. 2019 Jul 23;3(14):2128-2143. doi: 10.1182/bloodadvances.2019000222.
37	Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease.Biol Blood Marrow Transplant. 2008 Dec;14(12):1408-16. doi: 10.1016/j.bbmt.2008.09.022.
38	GLCCI1 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2015 Jul;21(7):1246-50. doi: 10.1016/j.bbmt.2015.03.015. Epub 2015 Apr 3.
39	Graft-versus-host disease-related cytokine-driven apoptosis depends on p73 in cytokeratin 15-positive target cells.Biol Blood Marrow Transplant. 2012 Jun;18(6):841-51. doi: 10.1016/j.bbmt.2012.02.004. Epub 2012 Mar 30.
40	A Novel Function for P2Y2 in Myeloid Recipient-Derived Cells during Graft-versus-Host Disease.J Immunol. 2015 Dec 15;195(12):5795-804. doi: 10.4049/jimmunol.1501357. Epub 2015 Nov 4.
41	Genome-wide single-nucleotide polymorphism analysis revealed SUFU suppression of acute graft-versus-host disease through downregulation of HLA-DR expression in recipient dendritic cells.Sci Rep. 2015 Jun 11;5:11098. doi: 10.1038/srep11098.
42	Toll-like receptor gene polymorphisms confer susceptibility to graft-versus-host disease in allogenic hematopoietic stem cell transplantation.Scand J Immunol. 2012 Sep;76(3):336-41. doi: 10.1111/j.1365-3083.2012.02737.x.
43	Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation.Blood. 1999 Oct 15;94(8):2911-4.
44	Host-microbe interactions in stem cell transplantation: recognizing Candida in infection and inflammation.Virulence. 2010 May-Jun;1(3):180-4. doi: 10.4161/viru.1.3.11208.
45	Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.Br J Haematol. 2018 Sep;182(6):887-894. doi: 10.1111/bjh.15492. Epub 2018 Jul 13.
46	DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation.Bone Marrow Transplant. 2002 Oct;30(8):497-502. doi: 10.1038/sj.bmt.1703658.
47	IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.Biol Blood Marrow Transplant. 2009 Feb;15(2):205-13. doi: 10.1016/j.bbmt.2008.11.015.
48	Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2015 Jul;21(7):1215-22. doi: 10.1016/j.bbmt.2015.04.010. Epub 2015 Apr 13.
49	Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program.N Engl J Med. 1998 Oct 22;339(17):1177-85. doi: 10.1056/NEJM199810223391701.
50	HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25133. Online ahead of print.
51	The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.Iran J Allergy Asthma Immunol. 2012 Mar;11(1):15-21.
52	Elevated level of HSPA1L mRNA correlates with graft-versus-host disease.Transpl Immunol. 2015 Jun;32(3):188-94. doi: 10.1016/j.trim.2015.02.002. Epub 2015 Feb 11.
53	Acute graft-versus-host disease is regulated by an IL-17-sensitive microbiome.Blood. 2017 Apr 13;129(15):2172-2185. doi: 10.1182/blood-2016-08-732628. Epub 2017 Jan 30.
54	Soluble interleukin-27 receptor alpha is a valuable prognostic biomarker for acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.Sci Rep. 2018 Jul 9;8(1):10328. doi: 10.1038/s41598-018-28614-4.
55	Characterization of Plasmodium berghei Homologues of T-cell Immunomodulatory Protein as a New Potential Candidate for Protecting against Experimental Cerebral Malaria.Korean J Parasitol. 2019 Apr;57(2):101-115. doi: 10.3347/kjp.2019.57.2.101. Epub 2019 Apr 30.
56	KIR2DS4 and Its Variant KIR1D Are Associated with Acute Graft-versus-Host Disease, Cytomegalovirus, and Overall Survival after Sibling-Related HLA-Matched Transplantation in Patients with Donors with KIR Gene Haplotype A.Biol Blood Marrow Transplant. 2016 Feb;22(2):220-225. doi: 10.1016/j.bbmt.2015.10.004. Epub 2015 Oct 22.
57	Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation.Blood. 2010 Apr 15;115(15):3162-5. doi: 10.1182/blood-2009-08-236943. Epub 2010 Feb 1.
58	Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation.Hum Immunol. 2016 Feb;77(2):176-83. doi: 10.1016/j.humimm.2015.11.015. Epub 2015 Nov 18.
59	Chromosome Y-encoded antigens associate with acute graft-versus-host disease in sex-mismatched stem cell transplant.Blood Adv. 2018 Oct 9;2(19):2419-2429. doi: 10.1182/bloodadvances.2018019513.
60	The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.Bone Marrow Transplant. 2019 Jul;54(7):1164-1167. doi: 10.1038/s41409-019-0453-0. Epub 2019 Jan 24.
61	Recombinant Pregnancy-Specific Glycoprotein 1 Has a Protective Role in a Murine Model of Acute Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2019 Feb;25(2):193-203. doi: 10.1016/j.bbmt.2018.09.022. Epub 2018 Sep 22.
62	Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling.Br J Haematol. 2003 Nov;123(4):671-5. doi: 10.1046/j.1365-2141.2003.04676.x.
63	HLA, GVHD, and parenteral nutrition are risk factors for hepatic complications in pediatric HSCT.Pediatr Transplant. 2016 Feb;20(1):96-104. doi: 10.1111/petr.12623. Epub 2015 Oct 31.
64	Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria.Leuk Lymphoma. 2016;57(4):835-41. doi: 10.3109/10428194.2015.1068309. Epub 2016 Feb 24.
65	TNFAIP8 Deficiency Exacerbates Acute Graft Versus Host Disease in a Murine Model of Allogeneic Hematopoietic Cell Transplantation.Transplantation. 2020 Mar;104(3):500-510. doi: 10.1097/TP.0000000000003013.
66	Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study.Clin Exp Dermatol. 2019 Mar;44(2):161-168. doi: 10.1111/ced.13678. Epub 2018 Jun 7.